Biotech

Helix BioPharma shared the publication of a peer-reviewed V-DOS47 manuscript in “Frontiers in Immunology” journal.

Helix BioPharma (TSX:HBP) shared the publication of a peer-reviewed V-DOS47 manuscript in “Frontiers in Immunology” journal.
As quoted in the press release:

V-DOS47 is Helix’s second DOS47 development candidate following L-DOS47, which is currently in clinical testing for the treatment of non-small cell lung cancer.
The article, entitled “Development and Characterization of a Camelid Single Domain Antibody-Urease Conjugate That Targets Vascular Endothelial Growth Factor Receptor 2”, describes the design and construction of V-DOS47 for breast cancer and other potential indications. The paper can be accessed online at https://doi.org/10.3389/fimmu.2017.00956.
“We are very pleased to present our V-DOS47 research work through a peer-reviewed forum,” said Heman Chao, Ph.D., Chief Executive & Scientific Officer of Helix. “V-DOS47 research and development activities, coordinated by our Polish subsidiary, Helix Immuno-Oncology S.A., have been progressing well. We continue to work closely with our team in Poland to advance the DOS47 platform.”

Click here to read the full press release.

Source: www.marketwired.com

MARKETS

Markets
TSX20383.77+39.70
TSXV575.64-5.68
DOW34347.03+152.97
S&P 5004026.12-1.14
NASD11226.36-58.96
ASX7259.50+17.70

COMMODITIES

Commodities
Gold1754.60+1.00
Silver21.61+0.03
Copper3.63+0.01
Palladium1856.61+10.62
Platinum984.00+3.00
Oil76.55-1.39
Heating Oil3.21-0.07
Natural Gas6.80-0.51

DOWNLOAD FREE REPORTS

×